Asymptomatic Severe Aortic Stenosis – Key Insights (ESC 2025)
Asymptomatic Severe Aortic Stenosis – Key Insights (ESC 2025)
1. Background
• Severe AS can remain silent for years.
• Once symptoms appear, prognosis worsens rapidly.
• Debate continues: Should we intervene early or wait until symptoms develop?
2. EARLY-TAVR Trial (NEJM 2025, presented at ESC 2025)
• ~900 patients with asymptomatic severe AS randomized to:
• Early TAVR vs Clinical surveillance.
• Findings:
• Early TAVR reduced the combined risk of death, stroke, and unplanned CV hospitalizations.
• Main benefit: fewer hospitalizations and lower stroke risk.
• Mortality difference: not yet significant.
3. Meta-analyses (JACC 2025, Généreux et al.)
• Early AVR (surgical or transcatheter) consistently lowers stroke and HF admissions.
• Impact on overall survival remains under investigation.
4. ESC 2025 Update
• New guidelines give Class IIa recommendation for early intervention in selected asymptomatic severe AS patients at low procedural risk.
• Key message: “Early action may prevent irreversible heart damage.”
5. Patient Selection Rules – When to Consider Early Intervention
• Severe high-gradient AS confirmed (AVA ≤1.0 cm², mean gradient ≥40 mmHg, Vmax ≥4.0 m/s).
• Truly asymptomatic (no angina, syncope, or HF; confirm with exercise testing if needed).
• Low procedural risk (suitable surgical/TAVR candidate without prohibitive comorbidities).
• Early signs of cardiac damage (LVEF <50%, LV hypertrophy/fibrosis, rising BNP/troponin).
• Rapid progression (Vmax increase ≥0.3 m/s/year or worsening echo findings).
• Age & anatomy fit (TAVR often for older patients; surgery for younger/low-risk).
6. Take-home Message
• Asymptomatic severe AS is no longer a passive “watch-and-wait” condition.
• Early TAVR/AVR is reasonable in well-selected patients to reduce hospitalizations and stroke, and to protect the heart before damage is irreversible.
• Careful patient selection remains the cornerstone.
